Mumbai-based Sun Pharmaceutical Industries Limited has announced one of the largest overseas acquisitions by an Indian company, agreeing to purchase New Jersey-headquartered Organon & Co. in an all-cash transaction valued at an enterprise value of $11.75 billion. The deal, revealed on April 26, 2026, marks a transformative step for Sun Pharma as it seeks to expand beyond its core generics business into higher-margin areas like women’s health and biosimilars.
Under the definitive agreement, Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in cash, representing a premium of more than 24% to Organon’s closing price on April 24, 2026. The transaction also includes the assumption of Organon’s approximately $8.6 billion in net debt. Both companies’ boards have approved the merger, with the deal expected to close in early 2027, subject to regulatory approvals and approval by Organon stockholders.
Organon, spun off from Merck & Co. in 2021, specializes in women’s health, biosimilars, and established medicines. It generated around $6.2 billion in revenue and $1.9 billion in adjusted EBITDA in 2025, with a portfolio of more than 70 products and six manufacturing sites across Europe and emerging markets. The company maintains a strong presence in over 140 markets, including significant operations in China and other high-growth regions.
For Sun Pharma, which reported similar revenue of about $6.2 billion last year, the acquisition will effectively double its top line to approximately $12.4 billion. This positions the combined entity among the world’s top 25 pharmaceutical companies. Sun Pharma also expects to emerge as one of the top three global players in women’s health and the seventh-largest biosimilar company worldwide. The deal aligns with Sun’s long-term strategy to diversify into innovative and specialty areas while leveraging its expertise in cost-efficient manufacturing and global distribution.
Executive chairman of Sun Pharma, Dilip Shanghvi, described the move as a significant opportunity, noting that Organon’s portfolio, capabilities, and global reach are highly complementary to Sun’s existing strengths. “This transaction represents a major milestone in our journey to build a global, innovation-driven pharmaceutical leader,” he stated. Organon’s executive chair, Carrie Cox, highlighted the compelling immediate value for stockholders and expressed confidence that Sun Pharma is well-positioned to support Organon’s businesses, employees, and patients globally.
The acquisition comes with expected cost synergies exceeding $350 million within two to four years. The combined company will operate across 150 countries, with 18 markets each contributing over $100 million in annual revenue. Sun Pharma plans to fund the deal through a mix of internal cash resources and committed bank financing.
Market reaction was positive. Shares of Sun Pharma rose around 7% following the announcement, reflecting investor confidence in the strategic fit. Organon shares jumped approximately 17%, closing in on the offered price.
This bold move underscores the growing ambition of Indian pharmaceutical giants on the global stage. By integrating Organon’s established brands and specialized focus areas, Sun Pharma aims to reduce dependence on lower-margin generics and accelerate growth in regulated markets, particularly the United States and Europe. The deal also strengthens its biosimilars pipeline and enhances its footprint in women’s health segments such as contraception, fertility, and hormone therapies.
Industry analysts view the transaction as a strategic masterstroke that could reshape competitive dynamics in key therapeutic areas. While integration challenges remain, including managing Organon’s debt levels, the long-term potential for revenue diversification and margin expansion appears substantial.
As the pharmaceutical industry continues to consolidate amid rising R&D costs and patent cliffs, Sun Pharma’s acquisition of Organon stands out as a landmark India-US cross-border deal. It signals confidence in the resilience of the global healthcare sector and the evolving role of emerging-market players in driving innovation and access worldwide.
